Report Highlights
The global market for drugs prescribed to treat mental health disorders should grow from $49.4 billion in 2020 to $62.6 billion by 2025 with a compound annual growth rate (CAGR) of 4.8% for the period of 2020-2025.
Report Includes
- 46 data tables and 12 additional tables
- An overview of the global markets for pharmaceutical treatments for mental health disorders
- Analyses of market trends, with data from 2019, 2020 and projections of compound annual growth rates (CAGRs) through 2025
- Evaluation of current market trends, market size, market forecast, pipeline analysis of new products, and regulatory scenarios and detailed analysis of drivers, challenges, and opportunities affecting market growth
- Description of biological factors such as anatomical, chemical and genetic traits, and psychological reasons such as conflict or trauma on the mental health and discussion on effect of COIVD-19 pandemic, social distancing and social isolation on the mental health conditions
- A look at the markets for treatment of psychiatric disorders such as depression, anxiety and obsessive-compulsive disorder (OCD) and their co relation with COVID-19
- Details of technological advances and improvement in the development of pharmacological treatments, digital therapeutics (DTx) and cognitive behavioural therapy (CBT)
- Information on tele mental health software such as ReSet, Pears Somryst and Alkili’s EndeavorRx which offers personalized treatment strategies and behavioural healthcare platform which plays an important role in the management of mental health disorders
- Snapshot of leading mental health conditions, and products in phase III development for selected psychiatric disorders
- Analysis of recent product developments including pharmacological and digital therapeutics, late-stage pipeline products and points of differentiation from existing therapies
- Market share analysis of the key companies of the industry, their strategic profiling, their competitive landscape and their detailed company profiles including, Eli Lilly, Johnson & Johnson, Pfizer, Takeda, and Shionogi
Report Scope
This new report on the market for pharmaceutical treatments for mental health disorders provides a brief overview of the pharmaceutical markets, current and future treatments, as well as drug failure/withdrawals and barriers to entry. It examines changes in healthcare regulation and guidance in the development of new agents and reviews activity in mergers and acquisitions that will help to change future treatment paradigms.
Analyst Credentials
Dr. Cheryl L. Barton has more than 10 years of practical pharmaceutical research experience with a leading pharmaceutical company and has served as a pan-European pharmaceutical analyst with a European bank. Dr. C. L. Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Her firm’s research reports combine independent scientific analysis with patients- and prescription-based models to forecast the potential sales growth of key developmental drugs and to isolate the key drivers within the pharmaceutical sector. For further information, visit www.pharmavision.co.uk
Related Reports
Mental Health Application: Technologies and Global Markets
The global market for mental health applications was valued at $2.5 billion in 2022. The market is estimated to grow from $3.0 billion in 2023 to $6.5 billion by 2028, at a compound annual growth rate (CAGR) of 16.6% from 2023 to 2028.
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets
The global central nervous system (CNS) biomarkers market should reach $9.5 billion by 2027 from $5.7 billion in 2022 at a compound annual growth rate (CAGR) of 10.8% for the forecast period of 2022 to 2027.
Digital Therapeutics: A New Age Medicine
The goal of this report is to understand the current digital therapeutics scenario and to assess the market’s growth potential. This study explores market dynamics that impact the growth of the market. The main objective of the study is to present a comprehensive analysis of the current market and the future direction of the market.
2021 Pharmaceuticals Research Review
BCC Research Market Report for generic drugs should grow from $411.6 billion in 2020 to $650.3 billion by 2025, at compound annual growth rate (CAGR) of 9.6%
Recent Reports
Drugs and Diagnostics for Hematological Disorders: Global Markets
The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.
Global Markets and Technologies for Advanced Drug Delivery Systems
The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Chagas Disease: American trypanosomiasis Market
The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More